QA Inside Bavarian Nordicʼs late stage stumbles  and drive to become a vaccine giant Despite the companyʼs recent Phase 3 setbacks in RSV and COVID19 CEO Paul Chaplin sees a path forward for the Danish biotech in the travel vaccine market